WednesdaySep 14, 2022 12:35 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat alcohol use disorder (‘AUD’) and major depressive disorder (‘MDD’). The substance is designed to achieve less variability in plasma levels, faster onset of action, shorter duration of effect, and potentially better tolerability than oral psilocybin for a better patient outcome overall. Earlier this summer, Cybin received a ‘may proceed’ letter and Investigational New Drug Application (‘IND’) clearance from the U.S.…

Continue Reading

MondaySep 12, 2022 10:00 am

TinyGemsBreaks – Mullen Automotive Inc.’s (NASDAQ: MULN) Acquisition of Controlling Stake in Bollinger Motors Featured in Recent Articles

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, was featured in recent articles published by InsideEVs and Newsweek that discussed its strategic move to purchase a controlling stake in Bollinger Motors. “EV fresh face Mullen Automotive has purchased a 60% controlling stake in Bollinger Motors for $148.2 million USD cash. It’s the company’s first EV acquisition after having purchased many of its building blocks from other enterprises along the way,” reads the Newsweek publication. The article quotes David Michery, CEO and chairman of Mullen Automotive, stating, “Combining Bollinger’s vehicles with our existing class 1 and class 2 EV…

Continue Reading

ThursdaySep 08, 2022 1:39 pm

TinyGemsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) on Leading Edge of Psilocybin Research

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions. The company is on the leading edge of a transformation that has seen the status of psilocybin evolve as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. “After a flurry of research in the 1950s and 1960s, psilocybin and all other psychedelics were abruptly banned, partly in response to their embrace by the counterculture. Following the 1971 United Nations Convention on Psychotropic Substances, psilocybin was classed in the U.S.…

Continue Reading

TuesdayAug 30, 2022 1:38 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Positioned ‘Front and Center for Last-Mile Delivery Opportunities’

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, owns and partners with several synergistic businesses to create clean and scalable EVs and energy solutions. “The company’s ability to reach this goal can perhaps be measured by its success, which was recently on display when Mullen inked a deal with DelPack Logistics LLC (‘DPL’) for up to 600 Mullen Class 2 Electric Cargo Vans. The two companies entered a binding agreement calling for DPL, an Amazon delivery service partner, to purchase the EVs over the next 18 months; the first 300 will be ready for delivery by Nov. 30,…

Continue Reading

MondayAug 29, 2022 1:43 pm

TinyGemsBreaks – Cepton Inc. (NASDAQ: CPTN) Taking MMT(R) Mainstream, Focusing Efforts on ‘Biggest Market for Lidar’

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, is taking Micro Motion Technology (“MMT(R)”) mainstream under the guidance of CEO and lidar pioneer Dr. Jun Pei. “Lidar uses lasers to generate 3D images and provides vital information including distance, speed and dimensions. This enables accurate detection tracking of objects based on real-time data. Emerging lidar applications include autonomous vehicles (‘AVs’), advanced driver assistance systems (‘ADAS’), traffic and pedestrian monitoring in smart cities, security and facility management, crowd analytics, and various industrial applications,” a recent article reads. “Cepton offers near-range to ultra-long-range lidar sensors, automotive software…

Continue Reading

MondayAug 29, 2022 1:33 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Streamlining NAFTA Region’s Cross-Border Shipping Process

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), through its Fr8App platform, offers a cloud-based marketplace that simplifies the once-complex process of international over-the-road (“OTR”) cross-border shipping. Innovative solutions offer quick and safe cross-border shipments while streamlining daily carrier operations. “The platform functions just as well for domestic, intra-country operations in each of the countries of the United States of America, Mexico or Canada. Because of this and other offerings in the Fr8Tech solutions suite, including but not limited to Fr8Radar, Fr8TMS and Fr8FMS, the company has come to be known for developing solutions to optimize and automate the supply chain process, offering…

Continue Reading

FridayAug 26, 2022 2:00 pm

TinyGemsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) on Target to Own, Control ‘the Elements’ to Supply EV, Renewable Energy, Other Technology Manufacturers

Energy Fuels (NYSE American: UUUU) (TSX: EFR) recently entered into binding agreements to acquire 17 mineral concessions in Brazil. A recent article reads: “The acquisitions, located in the state of Bahia and total approximately 58 square miles, have the potential to provide UUUU’s White Mesa Mill with large quantities of rare-earth-element and uranium-bearing natural monazite sand for decades. “This is another very significant step in Energy Fuels’ development as a major global rare earth element producer based in the United States,” said Energy Fuels CEO and President Mark Chalmers. “We are aggressively seeking to expand our monazite sand feeds. With…

Continue Reading

ThursdayAug 25, 2022 1:36 pm

TinyGemsBreaks – QSAM Biosciences Inc. (QSAM) Receives ‘Marketable Advantage’ Toward Manufacturing, Supply Chain of CycloSam(R)

QSAM Biosciences (OTCQB: QSAM) recently received a key patent for its exclusive radiopharmaceutical drug candidate, CycloSam(R), from the U.S. Patent & Trademark Office. “The patent protects how CycloSam is formulated and prepared, namely by using a nonradioactive kit that can be delivered and stored local to the administration site and provides for high purity in an efficient, facile and reproducible process at lower costs… The scope of this patent is fairly broad in that it not only protects the use of QSAM’s primary radioisotope, Samarium-153 (Sm-153), but also several other radioactive materials used in commercialized radiopharmaceuticals such as Lutetium-177 (Lu-177)…

Continue Reading

WednesdayAug 24, 2022 1:15 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Providing Industry Leading, Turnkey B2B iGaming, Esports Solutions

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, continues to leverage technological advances and incorporate them into its turnkey B2B solutions for online gambling operators. “Recent technological advances have made online gambling easier, more convenient and more enjoyable for some users when compared to a physical casino experience… GMGI appears to be on trend with the movement of users online and away from physical gambling, which has not recovered from COVID-19 business restrictions,” a recent article reads. “Golden Matrix leads the industry in providing turnkey B2B iGaming and Esports solutions for operators…

Continue Reading

TuesdayAug 23, 2022 1:26 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Continues Priority to Advance Clinical Development Program for Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is focused on advancing its clinical program for treating glioblastoma (“GBM”), a brain cancer that has no present cure and few treatment options for patients. The most aggressive primary brain tumor, GBM affects approximately 13,000 new patients each year in the United States with an average survival time of less than one year post diagnosis. “The company’s lead drug candidate is a novel anthracycline named Berubicin that has set itself apart from other potential therapies because of its apparent ability to cross the blood-brain barrier with central nervous system uptake,” reads a recent article. “CNS Pharmaceuticals…

Continue Reading

Contact us: (310) 299-1717